http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Chan-hong Park ),( Sungwook Chun ) 대한산부인과학회 2020 Obstetrics & Gynecology Science Vol.63 No.1
Objective This study aimed to assess the effect of combined oral contraceptives (COCs) on polycystic ovarian morphology (PCOM) and serum anti-Mullerian hormone (AMH) levels in Korean women with polycystic ovary syndrome (PCOS). Methods This university hospital study enrolled 36 Korean women who were newly diagnosed with PCOS based on the Rotterdam criteria and were treated with COCs for at least 1 year. We retrospectively evaluated the ovarian volume and number of antral follicles using ultrasonography and assessed serum AMH levels at baseline and after 1 year of COC treatment. Results Significant decreases in ovarian volume and antral follicle count were observed after 1 year of COC treatment. Compared to baseline, serum AMH levels were significantly decreased after 1 year. Conclusion COC treatment significantly affects ultrasound-assessed PCOM and serum AMH levels of patients with PCOS.
3세대 복합경구피임제 복용 중 발생한 심부정맥혈전증을 동반한 폐색전증
이의신,김무웅,류수정,은서준,박찬우,정종필,고영춘 조선대학교 의학연구소 2014 The Medical Journal of Chosun University Vol.39 No.3
Combined oral contraceptives (OCs) are a common method of contraception; however, they are associated with a twofold to sixfold increased risk of venous thrombosis (VT). The association between estrogen-containing OCs and VT is well established. After the first generation progestogens, new progestogens were developed. However, the risk of VT is higher for users of OCs with third generation progestogens than for those using second generation progestogens. We experienced a patient, a 25-year-old young woman with chest pain after taking third generation OCs. We performed chest computed tomography (CT) and lower extremity venogram CT. She was diagnosed with a pulmonary thromboembolism and deep vein thrombosis. She was treated with low molecular weight heparin and warfarin for six months. We report on this case with a review of the relevant literature.
Pulmonary embolism in a healthy woman using the oral contraceptives containing desogestrel
( Min-jeong Park ),( Gyun-ho Jeon ) 대한산부인과학회 2017 Obstetrics & Gynecology Science Vol.60 No.2
Venous thromboembolism is well known as one of the rare but serious adverse effects of combined oral contraceptives (COCs). The COCs with third and fourth generation progestogens were found to have higher risk of venous thrombosis than those with second generation progestogens. We present a case of pulmonary embolism in a 23-year-old nulligravid woman who was using COCs containing the third generation progestogen (desogestrel). At the time of presentation of the adverse effect, she had been using the COCs for 4 months. She had no additional risk factors for thrombosis such as smoking, surgery, tumor as well as genetic factors. This case demonstrates even young women in otherwise good health may be at risk of venous thromboembolism from low-dose formulations of COCs as an over-the-counter drug. We describe this case with a brief review of literatures.
( Nayoung Kim ),( Hana Yoo ),( Hyesun Hyun ),( Dongyun Lee ),( Byungkoo Yoon ),( Dooseok Choi ) 대한산부인과학회 2015 Obstetrics & Gynecology Science Vol.58 No.5
This study assesses the efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive, and demonstrates that it is an effective and safe option for contraception, releasing symptom of premenstrual dysphoric disorder and acne in Korean women.
( Yong-Su Jang ),( Eun Sil Lee ),( Yang-ki Kim ) 대한산부인과학회 2021 Obstetrics & Gynecology Science Vol.64 No.4
Objective Combined oral contraceptives (COCs) are used for various reasons. However, venous thromboembolism (VTE), a significant side effect, can be fatal. This study reports the first case series in Korea involving patients with COCassociated VTE registered at a university hospital. Methods This study recruited 13 patients diagnosed with COC-associated VTE between June 2006 and May 2018. Risk factors, including age, body mass index, smoking habits, estrogen dosage, type of progestin, and duration of COC use, were evaluated. Results Among patients with VTE, 9 showed pulmonary embolism (PE) concomitant with deep vein thrombosis (DVT). However, the remaining patients showed DVT (1 patient), PE (1 patient), and cerebral venous thrombosis (2 patients). The median duration between the onset of symptoms and a hospital visit was 3 days, and it sometimes took as long as 32 days. Among the 10 patients with PE, 1 high-risk group and 2 intermediate-high risk groups were treated with tissue plasminogen activators before anticoagulants. There were no cases of recurrence among patients who continued to take anticoagulants for 3 months. Conclusion These findings emphasize that healthcare professionals who prescribe or dispense COCs to women must inform them of the risk of VTE, including the risk factors, differences in risk depending on the type of progestin present in the product, and pertinent signs and symptoms. Efforts should also be made to inform patients of VTE, even through information campaigns such as brochures. Most importantly, women should remain alert for signs and symptoms of VTE when using COCs.
이재훈,송재연,이경욱,김진주,황규리,신정호,이지영,채희동 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.2
Coronavirus disease 2019 (COVID-19) is associated with a systemic inflammatory response that activates coagulation insymptomatic patients. In addition, a rare form of thrombosis has been reported in people who received the COVID-19vaccine, most of whom were women younger than 50 years of age. Considering that hormonal contraceptive methodswidely used by women of childbearing age increase the risk of thrombosis, the development of guidelines for theuse of hormonal contraceptives in the era of the COVID-19 pandemic is necessary. In this context, the Korean Societyof Contraception and Reproductive Health provides guidelines for issues regarding contraception and reproductivehealth during the pandemic.
Pereira, Nigel,Petrini, Allison C.,Zhou, Zhen N.,Lekovich, Jovana P.,Kligman, Isaac,Rosenwaks, Zev The Korean Society for Reproductive Medicine 2016 Clinical and Experimental Reproductive Medicine Vol.43 No.4
Objective: The aim of this study was to investigate the impact of pretreatment with transdermal estradiol ($E_2$) compared to oral contraceptive pills (OCPs) on controlled ovarian stimulation (COS) response in normal responders undergoing fresh in vitro fertilization (IVF)-embryo transfer (ET) cycles. Methods: A retrospective cohort study was performed of normal responders undergoing fresh IVF-ET cycles who received pretreatment with transdermal $E_2$ versus OCPs prior to fresh IVF-ET. The total days of ovarian stimulation, total dosage of gonadotropins, total number of oocytes, and mature oocytes retrieved were noted. Pregnancy outcomes after ET were also recorded. Results: A total of 2,092 patients met the inclusion criteria: 1,057 and 1,035 patients in the transdermal $E_2$ and OCP groups, respectively. Patients in the OCP group had a longer duration of COS ($10.7{\pm}1.63days$, p< 0.01) than the $E_2$ group ($9.92{\pm}1.94days$). Patients in the OCP group also required higher cumulative doses of gonadotropins ($2,657.3{\pm}1,187.9IU$) than those in the $E_2$ group ($2,550.1{\pm}1,270.2IU$, p= 0.002). No statistically significant differences were found in the total and mature oocytes retrieved or in the rates of biochemical pregnancy, clinical pregnancy, spontaneous miscarriage, and live birth between the groups. Conclusion: Our findings suggest that compared to OCPs, pretreatment with transdermal $E_2$ is associated with a shorter duration of ovarian stimulation and lower gonadotropin utilization, without compromising the oocyte yield or pregnancy outcomes in normal-responder patients undergoing fresh IVF.
Yang Wang,Victoria Nisenblat,Liyuan Tao,XinYu Zhang,Hongzhen Li,Caihong Ma 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.3
Objective: To evaluate the effectiveness of oral contraceptive pill (OCP) as therapy for endometrial hyperplasia (EH) without atypia in reproductive-aged women compared with oral progestin. Methods: A retrospective cohort study was carried out in our reproductive center. Consecutive patients diagnosed with infertility and non-atypical EH identified through electronic database who met inclusion criteria (n=309). Patients were assigned to two treatment groups: OCP (n=216) and oral progestin (n=93); clinical and reproductive outcomes were recorded. Results: Reversal of EH to normal endometrium, clinical pregnancy, live birth and miscarriage rate. Women in OCP group were younger, had higher prevalence of Polycystic Ovary Syndrome and other uterine pathology and longer duration of infertility than women in progestin group. Reversal of EH was observed in 93.52% women on OCP and in 86.02% women on progestin (p=0.032; adjusted odds ratio [aOR]= 2.35; 95% confidence interval [CI]=1.06-5.21) after the initial course of treatment for 2 to 6 months. Cyclic OCP (n=184) resulted in better response to treatment compared to continuous OCP (n=32) (95.11% vs. 84.38%; p=0.039; aOR =3.60; 95% CI =1.12-11.55). Clinical pregnancy rate in OCP group was marginally higher than progestin group (87/208, 41.83% vs. 27/90, 30.00%; p=0.054). Miscarriage (25.29% vs. 29.63%; p=0.654) and live birth rate (31.25% vs. 21.11%; p=0.074) were comparable between the groups. Conclusion: For the first time we demonstrate that OCP is an effective therapy for nonatypical EH and is associated with higher remission rate compared with oral progestin. Reproductive outcomes are reassuring and comparable between the two groups.
Use of Combined Oral Contraceptives in Perimenopausal Women
조문경 전남대학교 의과학연구소 2018 전남의대학술지 Vol.54 No.3
While perimenopausal women have low fecundity, they are still capable of becoming pregnant and the majority of pregnancies occurring during perimenopause are unintended pregnancies. Therefore, even during perimenopause, contraception must be used if unintended pregnancies are to be avoided. However, many perimenopausal women and healthcare providers believe that older people should not take combined oral contraceptives (COC) because doing so may be dangerous. However, to date, there is no evidence that taking COC presents an increased risk of cardiovascular events or breast cancer for middle-aged women as compared to other age groups, and in their recommendations, the Centers for Disease Control and Prevention (CDC) also do not list age itself as a contraindication for COC. Perimenopausal women often experience menstrual irregularity, heavy menstrual bleeding, and vasomotor symptoms. Taking COCs can help control these symptoms and significantly reduce the risk of ovarian cancer, endometrial cancer, and colorectal cancer. The objective of the present review is to examine the usage methods of COC among perimenopausal women and the health issues that may arise from taking COC in perimenopausal women.